Experimental cancer drug tested in patients with no other options

NCT ID NCT04550897

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called BM7PE immunotoxin in 14 people with colorectal cancer that had spread and was no longer responding to standard chemotherapy. The goal was to find a safe dose and see if it could help patients live longer. The study was stopped early, so we have limited information on how well it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

BM7PE immunotoxin

What this could lead to

If successful, this could offer a new treatment option for patients with advanced colorectal cancer who have run out of standard therapies.

What could go wrong

The trial was terminated early, so results are limited. It was a small, early-phase study, so safety and effectiveness are not yet proven.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Oslo University Hospital

    Oslo, Oslo, 0310, Norway